Clinical stage biotechnology company, ValiRx (VAL) announced to investors that their pre-clinical therapeutic compound, VAL301, has been granted a patent allowance in both Russia and China.
VAL301 is being developed for the treatment of “hormone-induced, non-oncological abnormal growth and cell proliferation conditions.”
Among these conditions are indications for benign prostatic hyperplasia, a noncancerous enlargement of the prostate, and endometriosis, an irregular tissue growth on ovaries or fallopian tubes.
The patents granted in Russia and China move to protect ValiRx for these indications, building on their receipt last year of a US patent grant.
Dr. Satu Vainikka, CEO of ValiRx, argued support from two of the world’s most populous countries proves ValiRx’s concept:
"These patent grant allowances are a further endorsement for VAL301. The pre-clinical and clinical development of the compound will benefit considerably from the earlier strong progress seen in the Phase I/II clinical trial of our prostate cancer therapeutic, VAL201, from which VAL301 is derived."
For more news and updates on ValiRx plc: